Search clinical trials for: Programmed Cell Death Ligand 2 (PD-L2, PDL2)

Total 96168 results

Thomas Marron

Recruiting

Dupilumab_Metastatic NSCLC

Metastatic Non-small Cell Lung Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Refractory Melanoma | HLA-A2 Positive Cells Present

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

Early Stage Non-small Cell Lung Cancer

China
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Squamous Cell Carcinoma of Head and Neck

United States, Australia, Canada, Denmark, France, Israel, Korea, Republic of, Norway, Portugal, Romania, Spain, Taiwan, United Kingdom, Colombia, Brazil
Merck Sharp & Dohme LLC

Active, not recruiting

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

Colorectal Cancer

United States, Poland, Belgium, Canada, Colombia, Costa Rica, Denmark, Estonia, France, Germany, Greece, Guatemala, Hungary, Italy, Korea, Republic of, Lithuania, Netherlands, Romania, Russian Federation, Spain, Turkey, United Kingdom
Merck Sharp & Dohme LLC
Gynecologic Oncology Group; European Network of Gynaecological Oncological...

Active, not recruiting

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

Poland, Korea, Republic of, United States, Australia, Belgium, Brazil, Canada, Chile, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Metastatic Hormone-Sensitive Prostate Cancer

China
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

Gastric Cancer | Gastroesophageal Junction Cancer

United States, Belgium, Brazil, Canada, Chile, China, Estonia, France, Germany, Guatemala, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Philippines, Poland, Russian Federation, Singapore, Taiwan, Ukraine, United...
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

Advanced Non-Small Cell Lung Cancer

Poland, Russian Federation, United States, Australia, Canada, Hong Kong, Ireland, Italy, Japan, Korea, Republic of, Singapore, South Africa, Spain, Switzerland, Taiwan, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)

Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Prostatic Neoplasms

United States, Argentina, Australia, Austria, Brazil, Canada, Chile, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Netherlands, Russian Federation, Spain, Taiwan, United Kingdom, Bulgaria, Czechia, Hu... and more
Merck Sharp & Dohme LLC

Completed

A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study

Non-small Cell Lung Cancer

China
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

Hodgkin Lymphoma
Merck Sharp & Dohme LLC

Completed

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Head and Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)

Ovarian Neoplasms
Merck Sharp & Dohme LLC

Completed

Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)

Metastatic Triple Negative Breast Cancer
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Melanoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)

Malignant Melanoma
Pfizer

Completed

An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis

Interstitial Cystitis | Painful Bladder Syndrome

Canada, United States, France, Denmark, Finland, Germany
Second Military Medical University

Unknown

Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)

Colorectal Carcinoma
Merck Sharp & Dohme LLC

Completed

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Lymphoma | Solid Tumors

United States, Korea, Republic of, France, Israel, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)

Colorectal Carcinoma
University of Padova
University Medical Center Groningen; Azienda Ospedaliera Universitaria Integrata... and other collaborators

Recruiting

European Prospective Registry on Anomalous Aortic Origin of the Coronary Arteries (EUROAAOCA)

Arrhythmia | Heart Defects, Congenital | Congenital Heart Disease | Sudden Cardiac Death | Surgical Procedure, Unspecified | Diagnosis | Adult Children | Coronary Artery Anomaly

Italy, Switzerland
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (KEYNOTE-B61)

Renal Cell Carcinoma

Poland, Australia, United States, Canada, France, Hungary, Ireland, Italy, Korea, Republic of, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Sun Yat-sen University

Recruiting

PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure

PD-1 Inhibitor | G-CSF

China
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

Renal Cell Carcinoma

United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Urothelial Cancer
Incyte Corporation
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Renal Cell Carcinoma (RCC)

Canada, France, United States, Spain, United Kingdom, Italy, Taiwan, Australia, Norway, Korea, Republic of, Germany, Russian Federation, Japan, Brazil, Turkey, Ukraine, Hungary, New Zealand, Chile, Ireland
Southeast University, China

Unknown

Immunoregulatory Therapy for 2019-nCoV

2019 nCoV, PD-1
Sheffield Teaching Hospitals NHS Foundation Trust
Dentsply International

Completed

Clinical Study Class II on Ceram.x Universal and Prime&Bond

Dental Caries

United Kingdom
Istituto Oncologico Veneto IRCCS

Completed

Epidemiological Features and Clinical Course of COVID -19 Infection in Cancer Patients: The Rovid Study

Solid Tumor, Adult

Italy
Fresenius Medical Care Deutschland GmbH

Completed

The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis

Chronic Renal Failure

Spain, Poland
University of Padova
Azienda Ospedaliera di Padova

Not yet recruiting

Assessing Detection Algorithms for Insulin Pump Malfunctions in Type 1 Diabetes

Diabetes Mellitus, Type I

Italy
University of Padova

Completed

Effects of Hypothermia on Delayed Neurocognitive Recovery (DNR): an Observational Trial Among Patients Undergoing Cardiac-Surgery (DNR)

Cognitive Dysfunction | Emergence Delirium | Hypothermia

Italy
University of Padova

Completed

A Mobile-App Training to Reduce Body Image Disorder Symptoms and Associated Features in Female University Students

Body Image Disorder | Body Dysmorphic Disorders | Eating Disorders

Italy
University of Padova

Unknown

Microbiota and Immune microEnvironment in Pouchitis (MEP1)

Ulcerative Colitis | Pouchitis | Ileal Pouch

Italy
University of Padova

Unknown

Treatment of Chronic Diabetic Foot Ulcers by Minimally Invasive Surgery (DiabeticMIS1)

Diabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities Foot

Italy
University of Padova

Unknown

Effect of Magnesium Supplementation in COPD

Pulmonary Disease, Chronic Obstructive

Italy
University of Padova
Azienda Ospedaliera di Padova

Unknown

Laryngeal Masks for Bariatric Surgery

Morbid Obesity

Italy
Merck Sharp & Dohme LLC

Completed

Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)

Melanoma

Australia, South Africa, Spain, Sweden
Cancer Institute and Hospital, Chinese Academy...

Unknown

GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma

Lymphoma | Tumor, Solid

China
Bristol-Myers Squibb

Withdrawn

Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy

Multiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin's Lymphoma | Chronic Myelogenous Leukemia
Peking University

Not yet recruiting

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Gazi University
Hacettepe University; Cukurova University; Marmara University; Istanbul University and other collaborators

Unknown

Evaluation of Status of Early Reached Target Enteral Nutrition and IFABP as Biomarker of Feeding Intolerance in Critically Ill Children (ERTENIFABPICU)

Enteral Nutrition | Feeding Intolerance | Intestinal Fatty Acid Binding Protein

Germany
Consorzio Oncotech

Completed

Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study (ARIES)

Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer

Italy
UCB Biopharma SRL

Active, not recruiting

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease (ORCHESTRA)

Early-stage Parkinson's Disease

United States, Canada, France, Germany, Italy, Netherlands, Poland, Spain, United Kingdom
Yale University
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Effect of Mental Imagery Training on Brain Plasticity and Motor Function in Individuals With Parkinson's Disease

Parkinson Disease

United States
Vifor Pharma, Inc.

Recruiting

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

Hyperkalemia

United States, Israel

Search clinical trials for: Programmed Cell Death Ligand 2 (PD-L2, PDL2)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations